Literature DB >> 9407960

Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.

J P Gibbs1, G Murray, L Risler, J Y Chien, R Dev, J T Slattery.   

Abstract

Busulfan, a bifunctional alkylating agent, is a mainstay of myeloablative preparative regimens before hematopoietic stem cell transplantation. The apparent oral clearance of busulfan expressed relative to body surface area is 2-3-fold higher in children 1-4 years old than it is in adults. The first step in busulfan elimination is the formation of a tetrahydrothiophenium ion (THT+) in a glutathione S-transferase-catalyzed reaction. We present computer simulations that demonstrate that the ratio of the AUC of THT+ to that of busulfan over 6 h [(AUC(THT+)/AUC(BU))(0-->6)] is highly correlated (r2 = 0.805) with the determinants of THT+ formation and is virtually independent of the determinants of its elimination (r2 = 0.0201). We compared (AUC(THT+)/AUC(BU))(0-->6) determined in 14 children (0.5-4 years) to that of 11 adults (12-54 years) and found a 1.5-fold elevation in the area ratio (P = 0.0098) and a similarly significant increase in busulfan apparent oral clearance expressed relative to body surface area (P = 0.042). The only common explanation for the elevated busulfan apparent oral clearance and (AUC(THT+)/AUC(BU))(0-->6) is an enhanced ability of children to metabolize busulfan through glutathione conjugation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407960

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Authors:  Radojka M Savic; Morton J Cowan; Christopher C Dvorak; Sung-Yun Pai; Luis Pereira; Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Rob F Wynn; Geoff D E Cuvelier; Peter J Shaw; Mary A Slatter; Janel Long-Boyle
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-09       Impact factor: 5.742

2.  Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.

Authors:  Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 4.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

5.  Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Authors:  Yvonne S Lin; Savannah J Kerr; Timothy Randolph; Laura M Shireman; Tauri Senn; Jeannine S McCune
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

6.  Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method.

Authors:  Manfred Rauh; Daniel Stachel; Michaela Kuhlen; Michael Gröschl; Wolfgang Holter; Wolfgang Rascher
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.

Authors:  Tiago Nava; Nastya Kassir; Mohamed Aziz Rezgui; Chakradhara Rao Satyanarayana Uppugunduri; Patricia Huezo-Diaz Curtis; Michel Duval; Yves Théoret; Liane E Daudt; Catherine Litalien; Marc Ansari; Maja Krajinovic; Henrique Bittencourt
Journal:  Br J Clin Pharmacol       Date:  2018-04-27       Impact factor: 4.335

8.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

9.  Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Arnon Nagler; Myriam Labopin; Norbert-Claude Gorin; Felicetto Ferrara; Miguel A Sanz; Depei Wu; Antonio Torres Gomez; Simona Lapusan; Giuseppe Irrera; Jose E Guimaraes; Aida Botelho Sousa; Angelo M Carella; Norbert Vey; William Arcese; Avichai Shimoni; Raanan Berger; Vanderson Rocha; Mohamad Mohty
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

10.  Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.

Authors:  F Léger; L Nguyen; C Puozzo
Journal:  Eur J Clin Pharmacol       Date:  2009-05-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.